The median level of expression of TNFR2, as measured by median fluorescence intensity (MFI) on Tregs (CD25hiFOXP3+), was also increased in ovarian cancer patients compared to benign ovarian masses and normal ovaries, respectively (840.6 versus 526.4 versus 326.4). This evidence concerns the gene TNFRSF1B and ovarian cancer.